1. Scrip
  2. >>Therapy Areas

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

 
• By Sukaina Virji and Emily Hayes

Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.

When Bristol-Myers Squibb Co. announced a couple months ago that the CheckMate 026 trial of its PD-1 inhibitor Opdivo (nivolumab) in first-line non-small cell lung cancer had failed, it was a major surprise. The failure in the exploratory analyses presented this weekend at the European Society for Medical Oncology, which could have been BMS's saving grace, were another shock, and have some totally re-forecasting the PD-1 market.

Final data for the CheckMate 026 first-line non-small cell lung cancer study, including exploratory analyses at different levels of PD-L1 expression, were presented during the Presidential Symposium at the European...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.